These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38754450)
1. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis. Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450 [TBL] [Abstract][Full Text] [Related]
2. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. Jenei K; Gentilini A; Haslam A; Prasad V Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098 [TBL] [Abstract][Full Text] [Related]
3. Project Orbis: Global Collaborative Review Program. de Claro RA; Spillman D; Hotaki LT; Shum M; Mouawad LS; Santos GML; Robinson K; Hunt M; Healy C; Chan A; Looi YH; Rodrigues C; Rohr UP; Walther C; Pazdur R Clin Cancer Res; 2020 Dec; 26(24):6412-6416. PubMed ID: 33037016 [TBL] [Abstract][Full Text] [Related]
4. Decision-Making at Swissmedic, the Swiss Regulatory Agency, with a Focus on (Neo)adjuvant Cancer Treatments. Zosso-Pavic M; Li Q; Juritz S; Gircys A; Wolfer A; Rohr UP Oncology; 2024; 102(10):907-912. PubMed ID: 38442691 [TBL] [Abstract][Full Text] [Related]
5. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners. Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651 [TBL] [Abstract][Full Text] [Related]
6. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration. Rohr UP; Iovino M; Rudofsky L; Li Q; Juritz S; Gircys A; Wildner O; Bujar M; Bolte C; Dalla Torre di Sanguinetto S; Wolfer A Clin Transl Sci; 2023 Sep; 16(9):1569-1581. PubMed ID: 37408165 [TBL] [Abstract][Full Text] [Related]
7. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996 [TBL] [Abstract][Full Text] [Related]
8. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. Salcher-Konrad M; Naci H; Davis C Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339 [TBL] [Abstract][Full Text] [Related]
9. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency. Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740 [TBL] [Abstract][Full Text] [Related]
10. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU. da Costa Gonçalves F; Demirci E; Zwiers A Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071 [TBL] [Abstract][Full Text] [Related]
11. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA. Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594 [TBL] [Abstract][Full Text] [Related]
12. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020. Vokinger KN; Serra-Burriel M; Glaus CEG; Rohr UP; Hwang TJ; Dalla Torre di Sanguinetto S; Kesselheim AS Ann Intern Med; 2023 Oct; 176(10):1413-1418. PubMed ID: 37844306 [TBL] [Abstract][Full Text] [Related]
13. New Oncologic Drugs from 2008 to 2023-Differences in Approval and Access between the United States, Europe and Brazil. Barreto RB; Izidoro AM; Miranda MHF Curr Oncol; 2024 Aug; 31(8):4443-4454. PubMed ID: 39195315 [TBL] [Abstract][Full Text] [Related]
14. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016. Kühler TC; Bujar M; McAuslane N; Liberti L BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082 [TBL] [Abstract][Full Text] [Related]
15. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program. de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899 [TBL] [Abstract][Full Text] [Related]
16. An Evaluation of the Swissmedic Regulatory Framework for New Active Substances. Bujar M; Dalla Torre di Sanguinetto SA; Kermad A; Bolte C; McAuslane N Ther Innov Regul Sci; 2024 Jan; 58(1):153-165. PubMed ID: 37884784 [TBL] [Abstract][Full Text] [Related]
17. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors. Shah RR; Roberts SA; Shah DR Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829 [TBL] [Abstract][Full Text] [Related]
18. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337 [TBL] [Abstract][Full Text] [Related]
19. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications. DiMasi JA Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388 [TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Arora S; Balasubramaniam S; Zhang W; Zhang L; Sridhara R; Spillman D; Mathai JP; Scott B; Golding SJ; Coory M; Pazdur R; Beaver JA Clin Cancer Res; 2020 Oct; 26(19):5062-5067. PubMed ID: 32295834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]